Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia.
Info & Links
CEO
George Lasezkay
Headquarters
900 NORTH POINT PARKWAY, SUITE 200 ALPHARETTA, GA 30005, UNITED STATES
Clearside Biomedical, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
66.44M
Enterprise Value
52.55M
Enterprise Value/EBITDA(ttm)
-2.12
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
10.14
Price to Book(mrq)
--
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
100.00%
Operating Margin(ttm)
-413.83%
Profit Margin(ttm)
-3592.23%
Return on Equity(ttm)
--
Return on Invested Capital(ttm)
133.25%
Return on Assets(ttm)
-92.90%
Income Statement
Revenue(ttm)
7.70M
Revenue Per Share(ttm)
0.10
Gross Profit(ttm)
7.70M
EBITDA(ttm)3
-24.77M
Net Income Available to Common(ttm)
-31.88M
Diluted EPS(ttm)
-0.45
Share Statistics
Beta (5Y Monthly)
2.22
52-Week Change
-34.71%
S&P 500 52-Week Change
18.02%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
75.84M
Dividend Yield
0.00%
Float4
68.87M
% Held by Insiders
9.20%
% Held by Institutions
18.75%
Balance Sheet
Total Cash(mrq)
23.59M
Total Cash Per Share(mrq)
0.31
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
4.49%
Quick Ratio(mrq)
4.49%
Book Value Per Share(mrq)
-0.47
Cash Flow
Operating Cash Flow Per Share(ytd)
-0.26
Free Cash Flow(ytd)
-19.98M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.